<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016080829268N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-06-11</date_registration>
      <primary_sponsor>Vice Chancellor for Research , Arak  University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the efficacy of memantine in children with attention deficit hyperactivity disorder</public_title>
      <acronym></acronym>
      <scientific_title>A Comparison of the Effect of Memantine added to Ritalin and Ritalin alone on cognitive Functions (Selective Attention, Sustained Attention, and Reverse Shot-term Memory) of Children with Attention Deficit and Hyperactivity Disorder (ADHD): A Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-04-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/23571</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Attention deficit hyperactivity disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: The research variables including severity of disorder, sustained attention, selective attention and reverse short-term memory were measured using Conners’ teacher and parent rating scales to measure attention deficit/hyperactivity disorder (ADHD), Conners’ Continuous Performance Test (Conners’ CPT Test), Stroop Test  and Wechsler Test, respectively. All these tests were done in the morning and, if possible, at a specific time.  After the tests, Ritalin tablet was prescribed according to a pediatric psychiatrist based on a dosage mentioned in a comprehensive and evidence-based listing book of dosage recommendations (Ritalin 10mg of Novartis Pharmaceuticals Corporation) at a dosage of 5 mg twice a day (½ tablet twice a day). If it has been well-tolerated, this dosage was increased to 10 mg twice a day and the Memantine Tablet (Alzantin 5mg TAB produced by Sobhan Pharmaceuticals Corporation) was administered simultaneously based on child’s weight (According to previous studies, Memantine dosage is set in terms of children’s weight).  If the child weighs more than 60 kg, 39-60 kg, 20-30 kg, less than 20 kg, a maximum daily dosage of 15 mg, 9mg, 6mg and 3mg is prescribed, respectively. The starting dosage of Memantine is 2.5 mg (½ Memantine 5mg Tab). If the previous dosage has been well-tolerated, 5 mg is added weekly to this dosage in terms of the target dosage and Memantine should be consumed for one month based on target dosage. After one month, the cognitive tests are repeated and the two groups are asked again to complete Conners’ teacher and parent rating scales. Intervention 2: Control Group: After obtaining informed consents from parents, The research variables including severity of disorder, sustained attention, selective attention and reverse short-term memory were measured using Conners’ teacher and parent rating scales to measure attention deficit/hyperactivity disorder (ADHD), Conners’ Continuous Performance Test (Conners’ CPT Test), Stroop Test  and Wechsler Test, respectively. All these tests were done in the morning and, if possible, at a specific time.  After the tests, Ritalin tablet was prescribed according to a pediatric psychiatrist based on a dosage mentioned in a comprehensive and evidence-based listing book of dosage recommendations (Ritalin 10mg of Novartis Pharmaceuticals Corporation) at a dosage of 5 mg twice a day (½ tablet twice a day). If it has been well-tolerated, this dosage was increased to 10 mg twice a day. After one month, the cognitive tests are repeated and Conners’ rating scales are completed by parents and teachers again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Omidi Fahimeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Postcode 3819693345, A'lam-Al-Hoda Street, Shahid Shiroodi Street, Arak, Markazi Province, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>+98 33 1360 5558</telephone>
        <email>f.omidi@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Omidi Fahimeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Postcode 3819693345, A'lam-Al-Hoda Street, Shahid Shiroodi Street, Arak, Markazi Province, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3819693345</zip>
        <telephone>+98 33 1360 5558</telephone>
        <email>amoozesh@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: The presence of hyperactivity disorder for both groups in children aged between 7-12 years old according to Statistical Manual of Mental Disorders, Fourth Edition (DSMIV).&#13;
Exclusion Criteria: The presence of neurological disorders; mental retardation disorders; disorders causing a decreased level of consciousness at the testing time; autism disorder; bipolar disorders; psychosis; depression and anxiety in terms of interviews with pediatric psychiatrist as well as drug side effects which led to drug intolerance.</inclusion_criteria>
      <agemin>7 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F90-F98</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>mental and behavioural disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: The research variables including severity of disorder, sustained attention, selective attention and reverse short-term memory were measured using Conners’ teacher and parent rating scales to measure attention deficit/hyperactivity disorder (ADHD), Conners’ Continuous Performance Test (Conners’ CPT Test), Stroop Test  and Wechsler Test, respectively. All these tests were done in the morning and, if possible, at a specific time.  After the tests, Ritalin tablet was prescribed according to a pediatric psychiatrist based on a dosage mentioned in a comprehensive and evidence-based listing book of dosage recommendations (Ritalin 10mg of Novartis Pharmaceuticals Corporation) at a dosage of 5 mg twice a day (½ tablet twice a day). If it has been well-tolerated, this dosage was increased to 10 mg twice a day and the Memantine Tablet (Alzantin 5mg TAB produced by Sobhan Pharmaceuticals Corporation) was administered simultaneously based on child’s weight (According to previous studies, Memantine dosage is set in terms of children’s weight).  If the child weighs more than 60 kg, 39-60 kg, 20-30 kg, less than 20 kg, a maximum daily dosage of 15 mg, 9mg, 6mg and 3mg is prescribed, respectively. The starting dosage of Memantine is 2.5 mg (½ Memantine 5mg Tab). If the previous dosage has been well-tolerated, 5 mg is added weekly to this dosage in terms of the target dosage and Memantine should be consumed for one month based on target dosage. After one month, the cognitive tests are repeated and the two groups are asked again to complete Conners’ teacher and parent rating scales.</i_keyword>
      <i_keyword>Control Group: After obtaining informed consents from parents, The research variables including severity of disorder, sustained attention, selective attention and reverse short-term memory were measured using Conners’ teacher and parent rating scales to measure attention deficit/hyperactivity disorder (ADHD), Conners’ Continuous Performance Test (Conners’ CPT Test), Stroop Test  and Wechsler Test, respectively. All these tests were done in the morning and, if possible, at a specific time.  After the tests, Ritalin tablet was prescribed according to a pediatric psychiatrist based on a dosage mentioned in a comprehensive and evidence-based listing book of dosage recommendations (Ritalin 10mg of Novartis Pharmaceuticals Corporation) at a dosage of 5 mg twice a day (½ tablet twice a day). If it has been well-tolerated, this dosage was increased to 10 mg twice a day. After one month, the cognitive tests are repeated and Conners’ rating scales are completed by parents and teachers again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Symptoms of hyperactivity and impulsivity. Timepoint: Before and one mounth after intervention. Method of measurement: Conners questionnaire for parents and teachers.</prim_outcome>
      <prim_outcome>Sustained attention. Timepoint: Continuous Performance Test (CPT). Method of measurement: Before and one mounth after intervention.</prim_outcome>
      <prim_outcome>Selective attention. Timepoint: stroop test. Method of measurement: Before and one mounth after intervention.</prim_outcome>
      <prim_outcome>Reverse short-term memory. Timepoint: Wechsler Digit Span Test. Method of measurement: Before and one mounth after intervention.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Adverse effect of Memantine. Timepoint: During the intervention and one month after intervention. Method of measurement: Observation and parents' narration.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research , Arak  University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-09-23</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Arak university of medical sciences ,Basij Sq,Sardasht,Arak Arak  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
